HR and breast carcinoma: A possible explanation may be the lack of specific treatment guidelines, which will require prospective randomized studies demonstrating the first-line combination of hormonal therapy and anti-Her2 therapy is superior to chemotherapy and anti-HER2 in metastatic HR+/HER+ breast cancer patients.